Roy Marie-Christine, Malo Marie-Françoise, Morel-Laforce Tierry, Ravitsky Vardit, Laberge Anne-Marie
Department of Social and Preventive Medicine, School of Public Health, University of Montreal, Montreal, Canada.
Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Prenat Diagn. 2025 Apr;45(4):453-463. doi: 10.1002/pd.6753. Epub 2025 Jan 31.
To explore decision makers' perspectives on the conditions for a responsible implementation of non-invasive prenatal testing (NIPT) as a first-tier test in Canadian provinces' healthcare systems.
A qualitative study was conducted with 16 Canadian decision makers who were interviewed between February 2021 and July 2022. After anonymization and transcription, interviews were coded inductively using thematic analysis.
Our interviews showed the complexity of the decision making environment regarding prenatal screening funding. Participants agreed that NIPT is superior to maternal serum screening as a first-tier test, but they also recognized that first-tier NIPT has limits and barriers. They described the following conditions for its responsible implementation: (1) need for time and evidence; (2) taking stakeholders' perspectives into account; (3) limit costs for the healthcare system; (4) ensure appropriate logistical conditions and harmonize the test offer; (5) ensure appropriate clinical services; (6) ensure informed consent; (7) ensure the test is presented as an individual choice to avoid eugenic concerns.
Multiple barriers and issues need to be addressed before moving NIPT from second- to first-tier. Decision makers' perspectives should be contrasted with those of other important stakeholders, including pregnant people, disability advocates and healthcare professionals.
探讨决策者对于在加拿大各省医疗保健系统中将无创产前检测(NIPT)作为一线检测进行负责任实施的条件的看法。
对16名加拿大决策者进行了定性研究,访谈时间为2021年2月至2022年7月。访谈进行匿名处理和转录后,采用主题分析法进行归纳编码。
我们的访谈显示了产前筛查资金决策环境的复杂性。参与者一致认为,作为一线检测,NIPT优于母体血清筛查,但他们也认识到一线NIPT存在局限性和障碍。他们描述了其负责任实施的以下条件:(1)需要时间和证据;(2)考虑利益相关者的观点;(3)限制医疗保健系统的成本;(4)确保适当的后勤条件并统一检测服务;(5)确保适当的临床服务;(6)确保知情同意;(7)确保将检测作为个人选择呈现,以避免优生学方面的担忧。
在将NIPT从二线检测转变为一线检测之前,需要解决多个障碍和问题。决策者的观点应与其他重要利益相关者的观点进行对比,包括孕妇、残疾权益倡导者和医疗保健专业人员。